Who Supplies Piperacillin to India from NETHERLANDS

Importing finished pharmaceutical formulations containing Piperacillin into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the Indian importer obtain necessary registrations and licenses. The foreign manufacturer must possess a valid manufacturing or wholesale drug license in their country. The Indian importer must obtain an Import Registration Certificate and an Import License from CDSCO. The application process involves submitting detailed product information, manufacturing details, and quality control data. The timeline for obtaining these approvals can vary but typically ranges from 3 to 6 months, depending on the completeness of the application and regulatory workload. Specific requirements for Piperacillin formulations under HS Code 30041090 include detailed product dossiers, stability data, and evidence of Good Manufacturing Practice (GMP) compliance.

Imported finished pharmaceutical formulations containing Piperacillin must undergo quality testing to ensure they meet Indian standards. CDSCO-approved laboratories conduct batch-wise testing, which includes verifying the Certificate of Analysis (CoA) provided by the manufacturer. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. The product must comply with the Indian Pharmacopoeia standards or demonstrate equivalence. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the shipments. The inspection process can take several days, and if a batch fails to meet the required standards, it may be rejected, leading to delays or the need for re-exportation.

Between 2024 and 2026, India has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements with the Netherlands have streamlined import procedures, reducing approval times and facilitating smoother trade. These changes aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.

India imports finished Piperacillin formulations to meet the demand for patented or branded products not manufactured domestically, as well as specific dosage forms required for patient care. The domestic capacity for producing certain Piperacillin formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Piperacillin formulations in India is substantial, with imports contributing significantly to the availability of these essential medicines.

The import duty structure for finished pharmaceutical formulations under HS Code 30041090 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. These duties are calculated on the Cost, Insurance, and Freight (CIF) value of the goods. Anti-dumping duties may also apply if the government determines that imports are being sold at unfairly low prices. Exemptions or reductions in duties can occur under specific Free Trade Agreements (FTAs) or government notifications. The total landed duty percentage can vary based on these factors and is subject to change with new regulations.

India sources finished Piperacillin formulations from the Netherlands due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. The Netherlands offers competitive advantages such as patented formulations and high-quality products that may not be available from other suppliers. Other countries, including China, Germany, and the United States, also supply Piperacillin formulations to India, but the Netherlands maintains a competitive position due to its established trade relations and consistent product quality.

India imports finished Piperacillin formulations from the Netherlands due to the availability of patented formulations, specialized dosage forms, and high-quality products that may not be manufactured domestically. The Netherlands's adherence to international quality standards and its established trade relations with India make it a preferred source for these formulations.

When compared to other origins such as China, Germany, and the United States, the Netherlands offers competitive advantages in terms of product quality, regulatory compliance, and reliability. While other countries may offer lower prices, the Netherlands's consistent quality and adherence to international standards provide a unique advantage for Indian importers seeking reliable sources for finished Piperacillin formulations.

Indian importers face several supply chain risks when sourcing finished Piperacillin formulations from the Netherlands, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, and maintaining robust quality assurance processes.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure flexibility in procurement.
5. 5Supplier Qualification: Conduct thorough due diligence to assess supplier reliability and compliance with quality standards.

1. DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.